Literature DB >> 9424998

Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect.

R E Simmonds1, H Ireland, D A Lane, B Zöller, P García de Frutos, B Dahlbäck.   

Abstract

BACKGROUND: Protein S is an important regulatory protein of the coagulation cascade. The risk for venous thrombosis associated with protein S deficiency has been uncertain because all previous risk estimates used phenotypic evaluation alone, which can be ambiguous.
OBJECTIVE: To quantitate the risk for thrombosis associated with a characterized protein S gene mutation that causes a Gly295-->Val substitution and protein S deficiency.
DESIGN: Retrospective study of a single extended family.
SETTING: University hospital referral center. PARTICIPANTS: A 122-member protein S-deficient family, in which 44 members had a recently characterized gene defect. MEASUREMENTS: Comprehensive history of thrombosis, history of exposure to acquired risk factors for thrombosis, levels of total and free protein S antigen, and genotype for the mutation causing the Gly295-->Val substitution.
RESULTS: Kaplan-Meier analysis of thrombosis-free survival showed that the probability of remaining free of thrombosis at 30 years of age is 0.5 (95% CI, 0.33 to 0.66) for carriers of the Gly295-->Val mutation compared with 0.97 (CI, 0.93 to 1.0) for normal family members (P < 0.001). In a multivariate Cox regression model that included smoking and obesity, the mutation was a strong independent risk factor for thrombosis (hazard ratio, 11.5 [CI, 4.33 to 30.6]; P < 0.001). For free (but not total) protein S antigen levels, the distributions of persons with and persons without the mutation did not overlap.
CONCLUSIONS: Protein S deficiency, as defined by the presence of a causative gene mutation or a reduced level of free protein S antigen, is a strong independent risk factor for venous thrombosis in a clinical affected family.

Entities:  

Mesh:

Year:  1998        PMID: 9424998     DOI: 10.7326/0003-4819-128-1-199801010-00002

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  13 in total

1.  Genetic polymorphisms in venous thrombosis and pulmonary embolism after total hip arthroplasty: a pilot study.

Authors:  Juergen Ringwald; Annika Berger; Werner Adler; Cornelia Kraus; Rocco P Pitto
Journal:  Clin Orthop Relat Res       Date:  2008-09-18       Impact factor: 4.176

2.  Implication of protein S thrombin-sensitive region with membrane binding via conformational changes in the gamma-carboxyglutamic acid-rich domain.

Authors:  D Borgel; P Gaussem; C Garbay; C Bachelot-Loza; T Kaabache; W Q Liu; B Brohard-Bohn; B Le Bonniec; M Aiach; S Gandrille
Journal:  Biochem J       Date:  2001-12-01       Impact factor: 3.857

3.  Superior mesenteric venous thrombosis associated with a familial missense mutation (Pro626Leu) in the SHBG-like domain of the protein S molecule.

Authors:  Miyuki Kato; Shinsuke Iida; Mikinori Sato; Yoshihito Hayami; Ichiro Hanamura; Kazuhisa Miura; Masato Ito; Shinsuke Harada; Hirokazu Komatsu; Atsushi Wakita; Tadao Manabe; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

4.  Reduced free protein S levels in patients with inflammatory bowel disease: prevalence, clinical relevance, and role of anti-protein S antibodies.

Authors:  S Saibeni; M Vecchi; C Valsecchi; E M Faioni; C Razzari; R de Franchis
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

5.  Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency.

Authors:  Elisabetta Castoldi; Lisbeth F A Maurissen; Daniela Tormene; Luca Spiezia; Sabrina Gavasso; Claudia Radu; Tilman M Hackeng; Jan Rosing; Paolo Simioni
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

Review 6.  Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery.

Authors:  Sean D Sullivan; Susan R Kahn; Bruce L Davidson; Lars Borris; Patrick Bossuyt; Gary Raskob
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 7.  Thrombophilias--practical implications and testing caveats.

Authors:  Stephan Moll
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

8.  Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis.

Authors:  William E Plautz; Vijaya Satish Sekhar Pilli; Brian C Cooley; Rima Chattopadhyay; Pamela R Westmark; Todd Getz; David Paul; Wolfgang Bergmeier; John P Sheehan; Rinku Majumder
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-02-01       Impact factor: 8.311

9.  Burden of rare exome sequence variants in PROC gene is associated with venous thromboembolism: a population-based study.

Authors:  Weihong Tang; Mary Rachel Stimson; Saonli Basu; Susan R Heckbert; Mary Cushman; James S Pankow; Aaron R Folsom; Nathan Pankratz
Journal:  J Thromb Haemost       Date:  2019-12-06       Impact factor: 5.824

10.  Free protein S level as a risk factor for coronary heart disease and stroke in a prospective cohort study of healthy United Kingdom men.

Authors:  Gie Ken-Dror; Jackie A Cooper; Steve E Humphries; Fotios Drenos; Helen A Ireland
Journal:  Am J Epidemiol       Date:  2011-09-12       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.